SCHEMBL437089

SCHEMBL437089

C=C(C)[Sn](CCCC)(CCCC)CCCC

nearest known ligand 0.33

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.33
LMNA P02545 3/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
THRB P10828 1/20 0.32
CES1 P23141 1/20 0.31
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
HSD17B10 Q99714 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7011373 0.88
Hydrochloric Acid SCHEMBL7011367 0.84
SCHEMBL203812 0.82 TSHR (0.33) TSHRLMNAALDH1A1SMN1; SMN2THRB
SCHEMBL1751456 0.78 ALDH1A1 (0.30) TSHRLMNAALDH1A1
SCHEMBL1899483 0.78 ALDH1A1 (0.30) TSHRLMNAALDH1A1
SCHEMBL4333058 0.76 ALDH1A1 (0.31) TSHRALDH1A1
SCHEMBL28831186 0.76
SCHEMBL28831243 0.76 CES1 (0.36) ALDH1A1CES1
SCHEMBL18421166 0.74 CES1 (0.40) TSHRALDH1A1CES1MEN1KMT2A
SCHEMBL28831280 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119518099-A Additive containing polyfluoroether functional groups and application of additive in battery 苏州浦昌新能源有限公司 2025-02-25 CN claimed
CN-119431969-A Method for preparing bathroom pad from nano antibacterial and mildew-proof environment-friendly material 浙江佳洁塑胶有限公司 2025-02-14 CN claimed
CN-117535841-A Preparation method of mildew-proof paper-based yarn 浙江舜浦新材料科技有限公司 2024-02-09 CN claimed
CN-114933758-A Quantum dot thin film material with gas-sensitive performance and application thereof 江苏烨湫传感科技有限公司 2022-08-23 CN claimed
CN-114540024-A Perovskite quantum dot material with gas-sensitive property and application thereof 江苏烨湫传感科技有限公司 2022-05-27 CN claimed
US-20260078122-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-03-19 US disclosed
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 US disclosed
CN-115515685-B EIF4E inhibitors and uses thereof 皮克医疗公司 2025-04-08 CN disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
CN-119518099-A Additive containing polyfluoroether functional groups and application of additive in battery 苏州浦昌新能源有限公司 2025-02-25 CN disclosed
CN-119431969-A Method for preparing bathroom pad from nano antibacterial and mildew-proof environment-friendly material 浙江佳洁塑胶有限公司 2025-02-14 CN disclosed
EP-0807621-A1 Derivatives of phenylglycine and use thereof as pharmaceuticals LILLY INDUSTRIES LIMITED (GB) 1997-11-19 EP disclosed
US-5604241-A Substituted benzylaminoquinuclidines as substance P antagonists PFIZER INC. (US) 1997-02-18 US disclosed
EP-0665843-A1 SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1995-08-09 EP disclosed
EP-0665844-A1 SUBSTITUTED BENZYLAMINOQUINUCLIDINES AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1995-08-09 EP disclosed
WO-1994010170-A1 SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1994-05-11 WO disclosed
WO-1994008997-A1 SUBSTITUTED BENZYLAMINOQUINUCLIDINES AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1994-04-28 WO disclosed
US-5258509-A Catalytic detherification and alkylation BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-11-02 US disclosed
EP-0430037-A2 Process for producing 2-carbon-substituted carbapenem derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1991-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 TSHR 3373/4885LMNA 4482/4885ALDH1A1 3129/4885
US-20260078122-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS PKN3, PKMYT1, IP6K3 TSHR 2477/4885LMNA 1004/4885ALDH1A1 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.